Best Skin Boosters for Under-Eye Rejuvenation: Clinical Review

The periorbital area — specifically the skin beneath the lower eyelid and around the orbital rim — is simultaneously the zone patients most frequently cite as their primary aesthetic concern and the zone where the consequences of incorrect product selection are most visible, most immediate, and most difficult to manage. Under-eye puffiness from a hydrophilic product, Tyndall effect from a misplaced crosslinked HA, or persistent oedema from too much volume in too small a space: all of these are avoidable outcomes that result from treating the periorbital zone with the same products and logic used elsewhere on the face.

Skin quality treatment of the periorbital area is one of the highest-value aesthetic services a practitioner can offer — patients who see genuine improvement in the appearance of tiredness and dark circles without the risks of tear trough filler are reliably among the most satisfied in any practice. But delivering that result requires a precise understanding of what the periorbital skin needs, what it cannot tolerate, and which product categories are clinically appropriate for this uniquely challenging zone.

This guide reviews the clinical evidence and product selection logic for under-eye biorevitalisation, covering the anatomy of the periorbital area, why standard skin boosters are often inappropriate here, which product properties are mandatory for this zone, and the injection protocols that produce the best outcomes. It is part of Celmade's Skin Booster content cluster — for the full guide, see the Complete Practitioner's Guide to Skin Boosters.

Periorbital Anatomy: Why This Zone Is Different

The periorbital skin is anatomically distinct from the rest of the face in ways that directly determine what can and cannot be safely or effectively used in this area. Practitioners who treat it as simply 'thin skin that needs a careful touch' miss the deeper anatomical reasons why the product requirements are so specific.

Skin Thickness

The eyelid and periorbital skin is the thinnest skin on the face — often 0.3–0.5mm in total thickness in the lower eyelid. For comparison, the cheek skin averages 2mm and the forehead 3–4mm. This extreme thinness means that any product placed intradermally in this zone is effectively at or very near the surface — and any product that causes swelling, holds water, or is placed even slightly too deep will be visible through the skin as discolouration, puffiness, or irregular surface texture.

The Orbicularis Oculi Muscle

The orbicularis oculi — the circular muscle surrounding the eye — runs directly beneath the periorbital skin. In the lower eyelid, there is minimal subcutaneous fat between the skin and the muscle in most patients. This means that any injection into the lower eyelid area that goes deeper than the superficial dermis will be placed directly into or below the muscle, not in subcutaneous fat as would occur in most other facial zones.

The Orbital Septum

Beneath the orbicularis oculi lies the orbital septum — a thin fibrous membrane that separates the orbit from the face. The orbital fat pad sits immediately behind this septum. In younger patients with an intact septum, the fat pad is contained. With age (or in patients with congenitally weak septa), the fat pad hernates forward, creating the characteristic under-eye bags of structural origin. This structural fat pseudohernia is not a skin quality problem — it is a structural/orbital anatomy problem — and cannot be improved by any injectable product. Distinguishing it from skin quality issues at consultation is critical to avoiding undertreated structural patients being sold a skin quality protocol.

Lymphatic Drainage

The periorbital area drains via the facial lymphatic network, and lymphatic drainage in this zone can be sluggish — particularly in older patients and those with subclinical inflammatory conditions. Any product with significant water-holding capacity (high hydrophilicity) will exacerbate this tendency, holding additional fluid in a zone where drainage is already limited. This is the anatomical basis for the risk of post-treatment lower eyelid oedema that occurs with highly hydrophilic products in this zone.

Why Standard HA Skin Boosters Are Often Inappropriate for the Periorbital Zone

Most HA skin boosters formulated for full-face biorevitalisation are inappropriate for use in the periorbital zone — not because intradermal HA is inherently wrong here, but because the specific formulation properties of standard skin boosters create risks that are uniquely amplified in this anatomy.

Required Product Properties for Periorbital Biorevitalisation

A product appropriate for periorbital skin booster treatment must meet all of the following criteria — not just some of them. Each property addresses a specific anatomical vulnerability of this zone:

•        Very low hydrophilicity: The product must not significantly attract or hold additional water beyond what it is injected with. This is the most critical property for the periorbital zone and the one that disqualifies the majority of standard HA skin boosters. Low hydrophilicity products cause less post-treatment swelling and maintain their volume without oedematous expansion.

•        Low concentration: A lower HA concentration reduces the total water-binding load introduced. For the periorbital zone, products in the 8–16 mg/ml range are preferable to standard 20–32 mg/ml formulations.

•        Low to very low molecular weight: Lower molecular weight HA chains penetrate tissue more readily, stimulate fibroblasts effectively, and have lower per-molecule water-holding capacity. For the periorbital zone, low MW or mixed MW products are preferred over high MW formulations.

•        Zero or near-zero G-prime: The product must integrate freely into tissue rather than maintaining any structural shape. Any firmness in a product placed in the periorbital dermis will be detectable and visible through the thin eyelid skin.

•        High cohesivity: Despite low G-prime, cohesivity should be reasonable — a product that disperses freely in all directions risks migration beyond the treated zone. Good cohesivity keeps the product within the intended tissue plane.

Product Categories Appropriate for Under-Eye Biorevitalisation

Given these requirements, three product categories are appropriate for periorbital biorevitalisation. Each has a different mechanism and clinical profile:

Category 1: PDRN / Polynucleotide Products

Polynucleotide products are the most appropriate category for under-eye biorevitalisation in the majority of patients. They address the periorbital zone's specific needs directly: they work through biological stimulation rather than mechanical hydration, so they carry none of the hydrophilicity-related oedema risk associated with HA products. PDRN/PN injected into the periorbital dermis activates adenosine A2A receptors on fibroblasts, stimulating collagen and elastin production and improving skin quality from within — without the water-attracting load that makes HA products problematic here.

•        Tyndall risk: Essentially zero — PN products are not visible through thin skin in the way that HA products can be.

•        Oedema risk: Very low — no significant hydrophilic mechanism.

•        Clinical result: Improvement in skin texture, reduction in crepey fine lines, and improvement in the dark circle component attributable to skin quality decline (rather than structural vascular causes). Results build over multiple sessions.

•        Korean PN products: Korean manufacturers — particularly those formulating products available through Celmade's PDRN and PN range — have been at the forefront of PN product development for periorbital use. Products specifically formulated for periorbital application, with appropriate concentration and molecular size, are available from CE-marked Korean manufacturers.

For the complete clinical guide to PDRN and polynucleotide products, see our Polynucleotides and PDRN: Complete Practitioners Guide. For the specific periorbital PN protocol, see Polynucleotides for Under-Eye Rejuvenation.

Category 2: Specialist Low-Hydrophilicity HA Skin Boosters

A limited number of HA skin booster products are specifically formulated with low hydrophilicity for periorbital use. These products use HA in concentrations and molecular weights carefully calibrated to provide biorevitalisation without the oedema risk of standard formulations. They are not the same as diluting a standard skin booster — the hydrophilicity of an HA product is a function of its formulation, not its concentration alone.

•        Product selection criteria: The product SPC or technical datasheet should specify low hydrophilicity. If this is not stated, do not assume the product is appropriate for periorbital use simply because it is low concentration.

•        Volume per injection point: 0.005–0.01ml maximum per point in the periorbital zone — significantly less than the 0.01–0.02ml used in standard face nappage.

•        Clinical result: Direct HA delivery to the periorbital dermis provides the immediate hydration and fibroblast stimulation of a skin booster without the hydrophilicity risk. Results are generally quicker in onset than PN-only protocols.

Category 3: Very Low Concentration / High Dilution HA

In the absence of a specialist periorbital-formulated product, some experienced practitioners use standard HA skin boosters at very high dilution (additional saline added to reduce the effective concentration per injection point) to reduce the hydrophilicity load. This is not ideal — hydrophilicity is a product property, not a concentration property — but at very high dilution (effective concentration < 8 mg/ml) and very small volumes per point, the risk profile is reduced compared to standard nappage volumes.

Periorbital Injection Protocol: Technique, Depth, and Volume

Periorbital injection technique must be the most precise and controlled of any skin booster application. Standard nappage principles apply but with modified parameters throughout:

Defining the Treatment Zone

The periorbital treatment zone for biorevitalisation is the skin of the lower eyelid and infraorbital region — specifically:

•        Superior boundary: The lower eyelash line (do not inject into the eyelid margin itself).

•        Inferior boundary: The infraorbital rim — stay above (or immediately below) the orbital rim. Do not inject significantly below the rim into the upper cheek — that is a different zone with different product requirements.

•        Medial boundary: The medial canthus — the inner corner of the eye. Do not inject medially beyond this point.

•        Lateral boundary: The lateral orbital rim — do not cross the rim laterally. Crow's feet treatment (which is not skin booster territory — it uses botulinum toxin) is a different zone.

Depth and the Tyndall Risk

The Tyndall effect is a bluish-grey discolouration visible through thin skin caused by the optical scattering of light through a superficially placed clear gel. It is most commonly associated with HA tear trough fillers placed too superficially — but it can also occur with skin boosters if the product is placed too superficially in the dermis and has sufficient volume to create a visible mass.

Prevention: use products with zero or near-zero G-prime, place at superficial dermal depth (not subdermal), use very small volumes per point (0.005–0.01ml), and use PN products rather than HA where HA-specific risk is a concern. If Tyndall effect occurs post-treatment with a skin booster HA product, hyaluronidase can be used to dissolve it — much more accessible than treating a HA filler-related Tyndall which may require higher doses.

Step-by-Step Periorbital Protocol

1.     Patient position: Supine. Elevate the head slightly to allow any dependent oedema to reduce before treatment.

2.     Apply topical anaesthetic: EMLA or equivalent under occlusion for 45–60 minutes. Remove completely with saline before injecting — no residue on the skin.

3.     Apply ice: Ice roller or wrapped ice pack for 2 minutes immediately before injecting each side. Causes mild vasoconstriction and provides additional anaesthesia.

4.     Stretch the skin gently: Use the non-dominant hand to gently stretch the infraorbital skin taut before each injection. This stabilises the thin mobile skin and allows more accurate needle placement.

5.     Inject at 15–20 degrees, bevel up: Advance the finest available needle (32–33G) to intradermal depth — approximately 1–2mm in this zone. The needle tip should be barely visible through the skin if it is correctly placed in the very superficial dermis.

6.     Deliver 0.005–0.01ml per point: A very small, transient papule should form. The papule here will be less prominent than full-face nappage papules due to the thin skin — do not attempt to deliver more product to see a larger papule.

7.     Withdraw and apply gentle pressure immediately: A cotton tip or sterile gauze pressed gently for 3–5 seconds after each injection reduces bruising risk.

8.     Work methodically: 5–10 injection points per side is typically sufficient for the under-eye zone. Work in a line or grid from medial to lateral, staying within the defined zone boundaries.

9.     Post-treatment: Apply ice immediately after completing each side. Cool the area for 3–5 minutes. Do not massage or press the treated area.

Managing Patient Expectations for Periorbital Treatment

Periorbital biorevitalisation produces subtle, progressive improvement rather than dramatic immediate results. Setting clear expectations at consultation is essential — particularly for patients who are hoping injectable treatment will resolve structural fat hernation or significant under-eye hollowing, which require different approaches.

Periorbital Biorevitalisation Treatment Protocol

Periorbital Biorevitalisation vs Tear Trough Filler: How They Work Together

Tear trough HA filler and periorbital biorevitalisation are not competing treatments — they address completely different anatomical problems and can be combined appropriately in patients who have both structural hollowing and skin quality decline in the same zone.

For practitioners who wish to offer tear trough filler in addition to periorbital biorevitalisation, see our Tear Trough Filler: Clinical Guide for Practitioners. For Korean CE-marked HA fillers with appropriate low G-prime and low hydrophilicity properties for the tear trough zone, see the dermal filler collection.

Key Takeaways

•        The periorbital zone requires specialist product selection — standard full-face skin boosters (high hydrophilicity, standard concentration) are inappropriate here and carry a high risk of post-treatment puffiness and oedema.

•        PDRN/PN products are the most appropriate primary choice — no hydrophilicity risk, excellent fibroblast stimulation, and specifically effective for the skin quality concerns patients present with in this zone.

•        If using HA, it must be low-hydrophilicity and specifically formulated for this zone — not standard skin booster products at reduced volumes, and not standard fillers.

•        Technique is more conservative than standard nappage throughout — 32–33G needle, 15–20 degree angle, 0.005–0.01ml per point, 10–20 points per side maximum.

•        Structural fat hernation is not a biorevitalisation indication — identify it at consultation and manage expectations before treating. Injectable treatment will not resolve this and may worsen the appearance.

•        Biorevitalisation and tear trough filler are complementary, not competing — filler addresses hollowing, biorevitalisation addresses skin quality. Separate sessions, 2–4 week interval, filler first.

•        Korean PDRN and PN products from Celmade are well-suited to this application — CE-marked, MFDS-approved, with formulations developed in the Korean market where periorbital PN treatment has been a clinical standard for years. Browse: PDRN and PN range and skin booster collection.

For related guides, see: Complete Skin Boosters Practitioners Guide, Polynucleotides and PDRN Guide, Polynucleotides for Under-Eye Rejuvenation, and Combining Skin Boosters with Other Treatments.

Frequently Asked Questions

Can I use a standard skin booster under the eyes?

Most standard full-face skin boosters — including high-concentration HA products — are not appropriate for use in the periorbital zone due to their hydrophilicity. Introducing a product that attracts and holds water into the periorbital dermis, where lymphatic drainage is limited and skin is extremely thin, frequently causes post-treatment lower eyelid puffiness. PDRN/PN products or specialist low-hydrophilicity HA formulations are the appropriate choices for this zone. For a full guide to PN periorbital treatment, see our Polynucleotides for Under-Eye Rejuvenation guide.

Will under-eye biorevitalisation fix dark circles?

It depends on the cause. Dark circles have multiple causes, and periorbital biorevitalisation addresses only those with a skin quality component. Causes that may respond: skin dehydration and thinning that increases the visibility of the underlying orbicularis muscle (which appears darkish through very thin skin), and surface pigmentation related to skin quality decline. Causes that will not respond: vascular dark circles (blue-purple discolouration from the superficial vessels visible through thin skin), structural shadows from tear trough hollowing, and true melanin hyperpigmentation. Accurately identifying the cause at consultation prevents unrealistic expectations.

How many sessions does under-eye biorevitalisation take?

The standard protocol is 3 induction sessions spaced 4 weeks apart, followed by maintenance every 3–4 months. Results are subtle after the first session and build progressively — most patients see meaningful improvement after the second or third session. Unlike full-face skin boosters where some practitioners extend maintenance intervals to 6 months, the periorbital zone typically benefits from more frequent maintenance (every 3–4 months) due to the area's continuous exposure to facial movement and expression.

Is the treatment painful under the eyes?

The lower eyelid area is more sensitive than most facial zones due to the high density of sensory nerves in this area. Thorough topical anaesthesia (EMLA applied for 45–60 minutes under occlusion) and ice application immediately before treatment significantly reduce discomfort. Most patients describe the sensation as a mild sharp sting at each injection point that lasts less than a second. The use of a 32–33G needle minimises injection trauma. Korean PN products with lidocaine in the formulation provide progressive anaesthesia as treatment proceeds.

What should I tell patients about bruising?

Bruising is more likely in the periorbital zone than in most other treatment areas due to the high vascular density and extremely thin overlying skin. Advise all patients to expect possible bruising, recommend avoiding alcohol and aspirin/NSAIDs for 24 hours before treatment, and use the finest available needle gauge (32–33G). Post-treatment topical arnica and ice can reduce bruising duration. For patients who are particularly concerned about bruising — performers, patients with important events — schedule the treatment at least 10–14 days before any important occasion.